Investigational Drug Details
| Drug ID: | D470 |
| Drug Name: | BAR502 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 1612191-86-2 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | 392.62 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | dual GPBAR1 and FXR agonist |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 1 on-going (NCT05203367) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0073 | NCT05203367 | Phase 1 | Not yet recruiting | No Results Available | February 25, 2022 | January 24, 2022 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A10928 | 31117231 | Nutrients | Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. | Details |
| A16758 | 28202906 | Sci Rep | BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. | Details |